<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31699">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01792518</url>
  </required_header>
  <id_info>
    <org_study_id>1218.89</org_study_id>
    <secondary_id>2012-002603-17</secondary_id>
    <nct_id>NCT01792518</nct_id>
  </id_info>
  <brief_title>MARLINA - T2DM : Efficacy, Safety &amp; Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin</brief_title>
  <official_title>A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety &amp; Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <authority>Denmark: The Danish Health and Medicines Authority</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>France: Agence Nationale sécurité médicament et des produits santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Philippines: Department of Health</authority>
    <authority>South Korea: Ministry of Food and Drug Safety (MFDS)</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Vietnam: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate linagliptin in terms of glycemic control as defined by HbA1c after 24 weeks of
      treatment and in terms of renal efficacy as defined by changes in albuminuria (UACR) after
      24 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in HbA1c</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time weighted average of percentage change from baseline in UACR</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">404</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>linagliptin 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>linagliptin 5 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo for linagliptin dose once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin 5mg</intervention_name>
    <arm_group_label>linagliptin 5mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of type 2 diabetes mellitus

          -  Glycosylated Hemoglobin (HbA1c) between 6.5 and 10% (inclusive)

          -  Current  therapy with ACEi or ARB at stable dose for 10 weeks

          -  Urinary albumin-to-creatinine ratio (UACR): 30-3000 mg/g creatinine documented in the
             previous 12 months or detected at Screening.

          -  Estimated Glomerular Filtration Rate (eGFR) greater than 30 ml/min.

          -  Age between 18 and  80 years.

        Exclusion criteria:

          -  Dual or triple blockade of the Renin Angiotensin System (RAS)

          -  Uncontrolled hyperglycaemia

          -  Mean arterial blood pressure &gt; 110 mmHg

          -  Known hypersensitivity or allergy to the investigational product, or their excipients
             (including matching placebos).

          -  Treatment with a glitazone within 6 months prior to informed consent.

          -  Treatment with a DiPeptidyl-Peptidase 4 (DPP-4) inhibitor, a Glucagon Like Peptide-1
             (GLP-1) agonist, a Sodium/Glucose coTransporter 2 (SGLT2) inhibitor, a
             dopamine-agonist, a bile-acid sequestrant or insulin (except basal insulin) within 10
             weeks prior to informed consent.

          -  Treatment with anti-obesity drugs 10 weeks prior to informed consent.

          -  Alcohol or drug abuse within 3 months prior to informed consent that would interfere
             with trial participation or any ongoing condition leading to a decreased compliance
             to study procedures or study drug intake in the opinion of the investigator.

          -  Current treatment with systemic steroids (glucocorticoids) at time of informed
             consent or change in dosage of thyroid hormones within 6 weeks prior to informed
             consent.

          -  Participation in another trial with an investigational drug within 2 months prior to
             informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1218.89.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.01011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melrose Park</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.01016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.11004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>1218.89.11008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.11006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.11009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.11002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.11003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.11007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.11005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gentofte</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.45004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.35803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kerava</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.35804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.33003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bersée</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.33005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourg des Comptes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.33007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grenoble Cedex 09</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.33010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Creusot</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.33008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Mandé cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.33004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vieux Condé</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.33011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vénissieux Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asslar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Flörsheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pirna</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schweinfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.81001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aoba-ku,Sendai,Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.81004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiyoda-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.81002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cyuo-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.81008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.81005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimizu-ku,Shizuoka city,Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.81006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita,Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.81007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Teine-ku,Sapporo,Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jinju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.82009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.63001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cebu City, Philippines</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.63002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cebu City, Philippines</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.63003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pasig City, Philippines</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.63004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Juan City, Philippines</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almeria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.34007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Sebastian de los Reyes</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.88004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.88011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.88008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.88003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.88002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.88005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.88010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.88006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.88009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.88001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.84001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hanoi, Vietnam</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.84006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hanoi, Vietnam</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.84002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hanoi, Vietnam</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.84004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.84005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1218.89.84003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>February 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuminuria</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>BI 1356</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
